The study design and protocol were accepted by the proprietors of the community pharmacies. The study protocol and informed consent form were approved by the Institute Human Ethics Committee kinase inhibitor Idelalisib of Sri Ramakrishna Institute of Paramedical Sciences. Written informed consent was obtained from each participant. Fifty patients were interviewed, of whom 39 participants met the inclusion criteria and were enrolled in the study. The literate (more than higher secondary level) and chronic diabetic patients (history of type 2 DM of more than 3 years) were included in the study and illiterate, children below 12 years of age, pregnant women, nursing mothers, type 1 DM patients and subjects with any other chronic disorders were excluded from the study.

Twenty of these participants were allocated randomly to the control group and 19 were allocated to the intervention group. Pharmacists had a discussion about the study with the eligible patients or their caregivers when prescriptions for diabetes medications were issued. Subjects were included if they had type 2 DM and gave informed consent. Patient background questionnaire The study participants completed a seven-item demographic questionnaire, providing information about their sex, age, marital status, education, income level, type of diabetes, length of time since diagnosis of diabetes and presence of other specific health problems. Diabetes Care Profile: An instrument of the study The data were collected using Diabetes Care Profile (DCP)??a questionnaire developed by J.J.

Fitzgerald of the Michigan Diabetes Research and Training Center (MDRTC), University of Michigan Medical School, Michigan. DCP Entinostat was developed as an instrument to assess social and psychological factors related to diabetes and treatment.[7,8] The questionnaire was translated into the local language, as is frequently done. The questionnaire was self-administered. It consists of 234 items including information on demography and self-care practices and 116 questions divided into 16 profile scales, including health status understanding, control problem and social and personal factors scales. The items were scored using a variable five-point Likert scale, in which 1 = good and 5 = poor,[9] and item scores were summed to gain a total score. Each scale was scored by summing certain item scores and dividing the sum by the appropriate number of items.

The interval between two visits was 2 months, and all the study subjects in the intervention group were interviewed a minimum of four times. DCP was performed in the 2nd and 8th months, and the results were compared. The study subjects were interviewed for a duration of 20?C40 min. Patients?? knowledge about diabetes and its management were tested at the baseline and final visits using Dovitinib clinical trial the MDRTC Brief Diabetes Knowledge Test Questionnaire. The questionnaire tests knowledge of 15 test items.